Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
Condition(s):Recessive Dystrophic Epidermolysis BullosaLast Updated:February 26, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):Recessive Dystrophic Epidermolysis BullosaLast Updated:February 26, 2020Unknown status
Condition(s):Small Cell Lung CancerLast Updated:May 25, 2018Withdrawn
Condition(s):Oropharyngeal Cancer; Human Papillomavirus-Related CarcinomaLast Updated:October 4, 2021Completed
Condition(s):PregnancyLast Updated:October 18, 2023Completed
Condition(s):Endometrial Cancer Stage I; Endometrial Cancer Stage IILast Updated:October 11, 2023Active, not recruiting
Condition(s):Breast Cancer Female; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8Last Updated:June 8, 2022Completed
Condition(s):Pancreas CancerLast Updated:January 29, 2024Not yet recruiting
Condition(s):Preterm BirthLast Updated:June 21, 2021Completed
Condition(s):Colorectal CancerLast Updated:October 13, 2017Recruiting
Condition(s):Hematologic CancerLast Updated:February 15, 2022Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.